A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-10. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
== See also == Bioengineering Directed evolution Hachimoji DNA List of genetic codes Nucleic acid analogue Non-proteinogenic amino acids Protein labelling Protein methods Synthetic biology Xenobiology
Such enthusiasm to use the Bryant Park name would have been nonexistent in the 1980s, when the area was described as "the Wild West". New real-estate developments were also built in the park's vicinity starting in the 21st century, which together added over 13,000 new workers to the area immediately surrounding Bryant Park. These included the Bank of America Tower; an expansion to 1095 Avenue of the Americas immediately to the south; Eleven Times Square a block west of Bryant Park; and 505 Fifth Avenue at Fifth Avenue and 42nd Street. Several hotels were also built, including a conversion of 485 Fifth Avenue at 41st Street, a Residence Inn by Marriott at Sixth Avenue and 39th Street. By the early 2010s, investors were purchasing buildings around Bryant Park south of 42nd Street as part of a small real estate boom. Rents per square foot in buildings south of 42nd Street had historically been lower than rents in buildings north of 42nd Street. Conversely, 1095 Avenue of the Americas and 452 Fifth Avenue were able to attract comparatively high rental rates despite both being south of 42nd Street. Later in the decade, the area around Bryant Park started growing into a residential neighborhood, with the construction of new developments in the area. Within a two-block radius of the park, or roughly 500 feet (150 m), units routinely sold for millions of dollars. By 2024, the Bryant Park Grill's lease was about to expire.
This shocks Minerva, who states that it leads to a world the Combine are sieging. Minerva betrays the protagonist after he sabotages the Combine's defenses, activating an orbital laser and attempting to destroy the base as she declares him a "redeemed traitor". He survives, however, and Minerva becomes apologetic, later admitting she has grown "attached" to him. She explains that the portal, wherever it may lead, could mean the difference between life and death for billions of people, hence her desperation to destroy it. She urges him to escape as she recharges the satellite's laser, as the Combine have become aware of her location and she fears retribution. With the aid of Minerva and a stolen helicopter, the protagonist fights to the surface and escapes the island just as it is annihilated by a second orbital blast. Minerva's communications are unusual in that each is prefixed by a time/date stamp in International Date Format (ISO 8601), giving an explicit timescale to the plot. These timestamps extend to several written pieces on the series's website that give background to the story. From these and the in-game messages it is possible to construct a partial timeline of events covered in the Minerva series.
Sources: en.wikipedia.org
=== Cancer === The estimated new cases of digestive system cancer in the Unitied States in 2023 was 348,840 and the estimated number of deaths from digestive system cancers was 172,010. The major specific causes of digestive system cancer related death in 2023 were cancers of the colon and rectum (52,550), pancreas (50,550), liver and intrahepatic bile duct (29,380), esophagus (16,120) and stomach (11,130). Bile acids, when present in specific regions of the digestive system at abnormally high levels, have been implicated as important carcinogens.
Bully: James Height: Weight: 200 lbs. Fighter: "Bad News" Ben Lagman Height: 6'2 Weight: 193 lbs. Victim(s): Sean (bully's co-worker) Money earned by Bully: $7,000 Money earned by victim(s): $3,000 Original airing: This episode was not aired on MTV in regular chronology with other episodes; it first aired on MTV2.
The activation of the endogenous opioids is for an analgesic effect using the gate control theory of pain. In addition, deep dry may also decrease pain, increase range of motion, and minimize myofascial trigger point irritability. In regards to the factor of pain reduction, relief occurs at four central levels: local pain, spinal pain through nerves, brain stem pain, and higher brain center pain. The relief of myofascial trigger points has been more highly researched than the relief of connective tissues, muscle fascia, muscle tension, and scar tissue; however, the American Physical Therapy Association claims that there potentially may be some benefits of dry needling on these ailments according to some available evidence. The APTA also claims that dry needling should not be used as a standalone procedure, but should be used in conjunction with other treatment methods, including manual soft tissue mobilization, neuromuscular re-education, functional retraining, and therapeutic exercises. Once the needle is inserted, one can manually or electrically stimulate the filiform needle depending for the desired effect of treatment.
Sources: en.wikipedia.org
The Bryant Park Corporation (BPC), formerly the Bryant Park Restoration Corporation (BPRC), manages the park. BPC also oversees the Bryant Park Management Corporation (BPMC), which was created to manage the Bryant Park business improvement district. Although Bryant Park is a public park, BPC accepts no public funds. It was initially supported by the Rockefeller Brothers Fund, but by the 21st century it received funding through tax assessments on surrounding property within the business improvement district, fees from concessionaires, and revenue from public events. As of 2024, the BPC raised about $29 million annually from sources such as rent payments and sponsorships. To obtain accurate data about park usage, BPC counts the number of patrons in Bryant Park at 1 p.m. and 6 p.m. every day.
Cereulide 2-methyl-5-HT Alpha-Methyltryptamine Bufotenin Chlorophenylbiguanide Ibogaine Phenylbiguanide Quipazine RS-56812 – Potent and selective 5-HT3 partial agonist, 1000× selectivity over other serotonin receptors SR-57227 Varenicline YM-31636 S 21007 (SAR c.f. CGS-12066A)
== Clinical significance == Tyrosine hydroxylase deficiency leads to impaired synthesis of dopamine as well as epinephrine and norepinephrine. It is represented by a progressive encephalopathy and poor prognosis. Clinical features include dystonia that is minimally or nonresponsive to levodopa, extrapyramidal symptoms, ptosis, miosis, and postural hypotension. This is a progressive and often lethal disorder, which can be improved but not cured by levodopa. Due to the low number of patients and overlapping symptoms with other disorders, early diagnosis and treatment remain challenging. Response to treatment is variable and the long-term and functional outcome is unknown. To provide a basis for improving the understanding of the epidemiology, genotype/phenotype correlation and outcome of these diseases, their impact on the quality of life of patients, and for evaluating diagnostic and therapeutic strategies, a patient registry was established by the noncommercial International Working Group on Neurotransmitter Related Disorders (iNTD). Furthermore, alterations in the tyrosine hydroxylase enzyme activity may be involved in disorders such as Segawa's dystonia, Parkinson's disease and schizophrenia. Tyrosine hydroxylase is activated by phosphorylation dependent binding to 14-3-3 proteins. Since the 14-3-3 proteins also are likely to be associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, it makes an indirect link between tyrosine hydroxylase and these diseases.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.